Both RMC-4550 (a SHP2 inhibitor) and RMC-6236 (a RAS (ON) multi-selective inhibitor) monotherapy exhibited anti-tumor activity in Class III BRAF-mutant NCI-H1666 parental and resistant cell lines, consistent with a previous report61. This evidence concerns the gene BRAF and neoplasm.